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Purpose: To investigate the long-term effects of multiple intravitreal injections on intraocular pressure
(IOP) in patients with exudative age-related macular degeneration, and to determine whether this is
related to a pre-existing diagnosis of glaucoma.
Methods: A retrospective study was carried out on 209 eyes in 173 patients with neovascular age-related
macular degeneration who received at least three intravitreal injections of bevacizumab or ranibizumab,
or both, from January 2006 to December 2012 at Shin Kong Wu Ho-Su Memorial Hospital. Sequential
changes in IOP following the intravitreal injections were documented and the incidence and charac-
teristics of the patients diagnosed with glaucoma were recorded and analyzed.
Results: Two hundred and nine eyes in 173 patients were included in this study. The mean number of
injections was 10.1 (range 3e23). No signiﬁcant change was found in IOP (p ¼ 0.41, paired t test) and
none of the patients experienced delayed ocular hypertension during the treatment course. No corre-
lation was found between differences in IOP and the number of injections (correlation coefﬁcient
0.086) and no signiﬁcant change in IOP was found in patients with or without glaucoma (p ¼ 0.42 and
0.37, respectively, paired t test). In addition, the use of drugs to lower IOP did not increase with repeated
intravitreal injections in patients with glaucoma [single drug, 24 (63.2%) patients; two drugs 14 (36.8%)
patients].
Conclusion: Repeated intravitreal antivascular endothelial growth factor injections of bevacizumab or
ranibizumab, or both, did not increase the risk of increasing IOP in patients with exudative age-related
macular degeneration, with or without glaucoma.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Exudative age-related macular degeneration (AMD), which is
characterized by the occurrence of a choroidal neovascular mem-
brane in the macular area, has become one of the most common
causes of severe impairment of visual function in elderly patients,
including those in Asia and Taiwan. For years, intravitreal injections
of antivascular endothelial growth factors (anti-VEGFs), such as
bevacizumab and ranibizumab, were the main treatment regimeny have no ﬁnancial or non-
tter or materials discussed in
ology, Sing-Kong Wu Ho-Su
strict, Taipei, Taiwan.
.-K. Cheng).
e Ophthalmologic Society of Taiwfor exudative AMD. As exudative AMD often runs a chronic, pro-
longed course with frequent recurrences of choroidal neovascular
membranes, multiple injections of anti-VEGFs are necessary for the
care of these patients. Aside from common ocular complications
such as postoperative infections, or inﬂammation and hemorrhage
in the vitreous or conjunctiva, the possibility of prolonged ocular
hypertension (OHT) has also been postulated to induce glaucoma.
Changes in intraocular pressure (IOP) after repeated intravitreal
injections of anti-VEGF have been thoroughly studied since anti-
VEGF treatment for exudative AMD was introduced. A transient
increase in IOP has been noted after anti-VEGF treatment for
exudative AMD; however, it is seldom sustained after a few weeks
of observation.1e7 The MARINA study observed no signiﬁcant long-
term changes in IOP after up to 2 years of follow-up.1 The AN-
CHOR2,3 and PIER4 study groups reported a transient increase in IOP
in some patients; however, it returned to baseline within a fewan. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic data for all 209 eyes in this study.
Characteristic Patients (n ¼ 173) Eyes (n ¼ 209)
Age (y), mean (range) 65.3 (58e82) 64.8 (58e82)
Male sex, n (%) 62 (35.8) 73 (34.9)
Comorbidity, n (%)
Hypertension 124 (71.7) 147 (70.3)
Diabetes mellitus 44 (25.4) 56 (26.8)
Lens status, n (%)
Phakic 102 (47.7)
Pseudophakic 112 (52.3)
Glaucoma, n (%) 27 (15.6) 39 (18.2)
No. of injections, mean (range) 10.2 (3e23)
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reported a short-term8e10 or even sustained increase11e20 in IOP
after intravitreal anti-VEGF treatment. Therefore, whether sus-
tained OHT is a delayed complication of intravitreal anti-VEGF
treatment has yet to be conﬁrmed.
The aim of this study was to investigate whether there was a
long-term effect on IOP in patients with exudative AMD who
received multiple intravitreal injections at different points during
treatment. We also investigated whether this was related to a pre-
existing diagnosis of glaucoma.
2. Methods
This was a retrospective study conducted at Shin Kong Wu Ho-
Su Memorial Hospital from January 2006 to December 2012. All the
patients receiving intravitreal injections of bevacizumab or rani-
bizumab, or both, were informed about the drugs, including the off-
label use of bevacizumab, and all agreed to the treatment. This
study followed the tenets of the Declaration of Helsinki and was
approved by the Institutional Review Board of Shin KongWu Ho-Su
Memorial Hospital.
Data on 209 eyes in 173 patients with neovascular AMD who
received at least three intravitreal injections of bevacizumab or
ranibizumab, or both, were collected, together with the treatment
course. Demographic information, systemic comorbidities, lens
status, ocular surgery, number of injections, use of drugs to lower
IOP, and IOP at baseline and at each visit were recorded. The
endpoint was the last visit during this study period.
The patients were diagnosed with neovascular AMD based on
clinical symptoms, optical coherence tomography (OCT), ﬂuores-
cein angiography, and indocyanine green ﬁndings. The exclusion
criteriawere: glaucoma that was not well controlled before the ﬁrst
injection (baseline IOP >21 mmHg); previous ocular surgery
complicated with OHT; polypoidal choroidal vasculopathy as
diagnosed by indocyanine green angiography (ICGA) and other
ocular disease including proliferative diabetic retinopathy, retinal
vein or artery occlusion, uveitis and other ocular inﬂammatory
diseases; and intraocular surgery during the course of treatment.
The intravitreal injections were performed under local anes-
thesia with 0.5% proparacaine hydrochloride eye drops. Before in-
jection, the periocular skin was disinfected with 5% povidonee
iodine solution and draped as per standard procedures. The intra-
vitreal injections were performed at 3.5e4.0 mm posterior to the
limbus in phakic eyes, or 3.2e3.5 mm posterior to the limbus in
pseudophakic and aphakic eyes with a 30-gauge needle, with
intravitreal injections of bevacizumab 2.5 mg/0.1 mL after anterior
chamber tapping for 0.05 mL or intravitreal injections of ranibi-
zumab 0.5 mg/0.05 mL after anterior chamber tapping for 0.05 mL,
or both.
After the procedure, topical 0.25% chloramphenicol and 1%
prednisolonewere given four times a day, and Codemycin ointment
(Oasis, Taipei, Taiwan; hydrocortisone acetate 0.1% þ neomycin
sulfate 0.05%) was given before bed for 3 days for the prophylaxis of
infection and inﬂammation. The patients were then instructed to
visit our clinic 1 week after the procedure and were followed
monthly to decide whether reinjection of the anti-VEGF was
necessary. The decision to reinject was based on an “as-needed”
principle and the patients were advised to receive a reinjection if:
(1) any subretinal ﬂuid or cystic changes were persistent or reap-
peared in OCT examinations; (2) there was a marked increase in
serous or hemorrhagic pigment epithelial detachment on OCT ex-
aminations; or (3) any hemorrhagic complications were noted on
fundus examinations. Complete ocular examinations, including
best corrected visual acuity, IOP, slit-lamp biomicroscopy, fundus
ophthalmoscopy, and OCT, were performed at each follow-up visit.IOPwas recordedwith a non-contact tonometer (NIDEK NT-530,
NIDEK Inc., Tokyo, Japan) without local anesthesia and before the
application of a mydriatic agent. Changes in IOP were identiﬁed as
the difference between the IOP before and 1 week after each in-
jection. Delayed OHT was deﬁned as either an IOP 22 mmHg at
two consecutive visits with an increase from baseline>6mmHg, or
a single IOP increase of >26 mmHg with concomitant initiation or
increase in the use of IOP-lowering treatment. Changes in IOP were
analyzed with paired t tests.
The patients were then divided into subgroups of those with
glaucoma and those without glaucoma. Glaucoma was diagnosed
based on funduscopy and OCTevidence of optic disc or retinal nerve
ﬁber layer (RNFL) structural abnormalities or visual ﬁeld damage
consistent with retinal nerve ﬁber layer damage, or both. Only eyes
with neovascular AMD that received intravitreal injections were
taken into consideration. Changes in IOP between the patients with
and without glaucomawere analyzed with independent t tests. The
incidence and characteristics of the patients diagnosed with glau-
coma, demographic data, and sequential IOP changes following the
intravitreal injections were analyzed.
3. Results
Two hundred and nine eyes in 173 patients were included in this
study. In total, 2132 injections of anti-VEGF were performed,
including 2071 injections of bevacizumab and 61 injections of
ranibizumab. One hundred and eighty eyes received intravitreal
injections of bevacizumab monotherapy, and 29 eyes received both
intravitreal injections of bevacizumab and ranibizumab sequen-
tially. The mean age of the patients was 65.3 years (range 58e82
years) and 73 (34.9%) were men. A total of 70.3% of eyes were in
patients with hypertension and 26.8% were in patients with dia-
betes mellitus. The mean number of injections was 10.1 (range 3e
23). Table 1 summarizes the demographic data for the patients.
There was no signiﬁcant change in IOP (p ¼ 0.41, paired t test) and
none of the patients experienced delayed OHT during the treat-
ment course. There was no correlation between the difference in
IOP and the number of injections (Fig. 1; correlation
coefﬁcient 0.086).
Thirty-eight of the 209 (18.2%) eyes were diagnosed with open
angle glaucoma. The pre-injection mean  standard deviation IOP
was 15.3  2.43 mmHg in the patients with glaucoma, and
13.2  3.47 mmHg in the patients without glaucoma. The mean
numbers of injections were 9.1 and 10.3 in the patients with and
without glaucoma, respectively. The changes in IOP
were þ0.28  0.74 mmHg in the patients with glaucoma,
and þ0.26  0.81 mmHg in the patients without glaucoma. No
signiﬁcant change in IOP was found in either group (glaucoma
group p ¼ 0.42; without glaucoma group p ¼ 0.37; paired t test).
The use of IOP-lowering drugs did not increase with repeated
intravitreal injections. An increase in IOP was not found in both
Fig. 1. Plot of difference in intraocular pressure versus number of injections showing
that there was no correlation between these two variables (correlation
coefﬁcient 0.086). IOP ¼ intraocular pressure.
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coma did not increase during the treatment, which implied that the
status of glaucoma was stationary, including changes in IOP,
cupping/disc (C/D ratio), or RNFL. Table 2 shows the characteristics
of the patients diagnosed with glaucoma compared with those
without glaucoma.4. Discussion
In this retrospective study of 209 eyes (173 patients) treated for
exudative AMD with intravitreal anti-VEGF injections (bev-
acizumab or ranibizumab, or both), we did not ﬁnd a signiﬁcant
increase in IOP in the patients either with or without pre-existing
glaucoma. In addition, no patient had OHT (deﬁned as IOP
22 mmHg on at least two consecutive visits with an increase from
baseline>6mmHg or an IOP spike>26mmHg). Furthermore, there
was no correlation between the number of injections and the mean
increase in IOP after anti-VEGF injection (Fig. 1).
Our results are consistent with previous large-scale prospective
randomized clinical trials such as theMARINA and ANCHOR studies
that did not report any cases of delayed OHT in patients receiving
monthly injections of ranibizumab over 2 years for exudative
AMD.1e3 A recent study conducted byWehrli et al21 also reported a
lack of delayed increase in IOP in eyes treated with anti-VEGF
(bevacizumab or ranibizumab, or both) compared with theTable 2
Demographic data of the patients with and without glaucoma. All the patients were
followed up for at least 6 months after the latest treatment.
Characteristics With glaucoma Without glaucoma
No. of eyes (%) 38 (18.2%) 171 (81.8%)
IOP before injection (mmHg),
mean  SD
15.3  2.43 13.2  3.47
Final IOP change (mmHg),
mean  SD
+0.28  0.74 +0.26  0.81
p 0.42 0.37
No. of drugs for IOP
control (per eye)
Initial, mean  SD 1.42  0.52 None
Final, mean  SD 1.47  0.49 None
p 0.89 N.A.
Transient increase in IOP None None
No. of injections,
mean  SD (range)
9.1  4.52 (3e19) 10.3  5.82 (3e23)
IOP ¼ intraocular pressure.untreated fellow eyes in patients with exudative AMD. As in the
current study, these workers also compared patients with a pre-
vious diagnosis of glaucoma (32 eyes) and those without glaucoma
(270 eyes) and found that there was no signiﬁcant difference in the
incidence of delayed OHT in either group. Another study conducted
by Sobaci et al22 also reported no signiﬁcant difference in the in-
crease in IOP or changes in the nerve ﬁber layer in patients with
exudative AMD treated with anti-VEGF compared with untreated
control eyes.
However, whether or not an increased incidence of delayed OHT
or a gradual increase in mean IOP exists in patients treated with
repeated injections of anti-VEGF is controversial. Since the begin-
ning of the use of anti-VEGF for the treatment of exudative AMD,
persistent OHT after repeated intravitreal injections has been re-
ported in several anecdotal case reports. Kahook et al11 reported
persistent OHT in six patients treated with single or multiple
intravitreal bevacizumab injections for exudative AMD (ﬁve pa-
tients) and myopic choroidal neovascular membrane (one patient).
Bakri et al12 reported four patients with persistent OHT in the range
30e50 mmHg after intravitreal ranibizumab injections for exuda-
tive AMDwho required control with ocular antihypertensive drugs.
Several larger retrospective studies have reported the frequency
of sustained OHT in patients with exudative AMD treatedwith anti-
VEGF to be between 3.45% and 11.6% according to different deﬁ-
nitions of persistent OHT and the duration of follow-up.13e19
Adelman et al13 reported that of 116 patients with exudative
AMD without a history of glaucoma or OHT, four (3.45%) were
found to have persistent OHT (IOP >21 mmHg in 2 separate mea-
surements) from 3 to 36 months after repeated intravitreal in-
jections of bevacizumab or ranibizumab, or both. Choi et al15
reported an incidence of 5.5% (7 in 127 patients) of sustained
increased IOP (deﬁned as IOP >25 mmHg on 2 separate visits
requiring drugs for glaucoma, or surgery) in patients with exuda-
tive AMD treated with anti-VEGF (ranibizumab, bevacizumab, or
pegaptanib, or a combination of these drugs) during a follow-up
period ranging from 30 days to 1759 days.
Tseng et al16 identiﬁed 21 eyes of 19 patients with exudative
AMD with a sustained increased IOP (using a deﬁnition of IOP
>21 mmHg detected during at least 2 consecutive clinic visits or an
increase in IOP requiring treatment, or both), which represented
3.4% of the total number of patients (555 patients) with exudative
AMD treated with anti-VEGF at the doctor’s clinic over a period of
62 months. Hoang et al18 initially reported a frequency of 11.6% of
persistent OHT (>5 mmHg increase from baseline IOP on two
consecutive visits) in 207 patients followed from 48.1 to 260.0
weeks. The same study group19 later reported a 7.1% rate of sus-
tained increased IOP (deﬁned as an absolute IOP >25 mmHg, in-
crease above baseline >10 mmHg, or IOP of >21 mmHg and
increase of >5 mmHg) in 449 eyes of 328 patients with exudative
AMD treated with anti-VEGF from 66.3 to 262.7 weeks.
The mean IOP has also been reported to be increased after
intravitreal anti-VEGF injections for exudative AMD. In a retro-
spective study of 320 patients with exudative AMD treated with
intravitreal ranibizumab, Menke et al20 found a small but signiﬁ-
cant increase (0.8  3.1 mmHg) in IOP after a mean of 13.0  8.0
injections over a mean follow-up period of 22.7  14.1 months.
However, they did not identify any patient with a ﬁnal IOP
>25 mmHg in their series.
Pre-existing or concurrent glaucoma has been proposed to be a
possible reason for persistent OHT after repeated anti-VEGF in-
jections for exudative AMD. In the six patients with persistent OHT
reported by Kahook et al,11 three had a previous history of glau-
coma and another patient had current evidence of glaucomatous
cupping and visual ﬁeld defect. Good et al14 also reported that in
216 eyes treated with anti-VEGF for exudative AMD, the patients
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IOP than patients without pre-existing glaucoma (33% vs. 3.1%,
respectively; p < 0.001). They suggested the possibility of a
heightened risk of a further increase in IOP in patients with pre-
existing glaucomawho receive either bevacizumab or ranibizumab.
The connection of persistent OHT with pre-existing glaucoma
has not been supported by other studies, however. None of the
patients with persistent OHT reported by Bakri et al12 and by
Adelman et al13 had a previous ocular or family history of glaucoma,
suspected glaucoma, OHT, or asymmetric IOP. In the case series of
Tseng et al,16 20 of 25 eyes that were identiﬁed as having persistent
OHT were not associated with a prior history of glaucoma or prior
intravitreal corticosteroid injection. Neither our series nor the se-
ries of Wehrli et al21 found an increased risk of sustained increased
IOP or increased number of drugs for glaucoma in patients with a
prior history of glaucoma. Thus it is possible that a prior history of
glaucoma may not be an important factor in inducing persistent
OHT in patients with AMD treated with anti-VEGF injections.
The possible mechanisms for persistent OHT in patients with
exudative AMD after repeated intravitreal anti-VEGF injections are
still not well understood. One possible mechanism is direct damage
of the trabecular meshwork by anti-VEGF treatment. However, this
mechanismwas not supported by a study inwhich no toxic effect of
bevacizumab was found on cultured human trabecular meshwork
cells.23 Another proposed mechanism is intraocular inﬂammation
such as anterior uveitis and trabeculitis.12 Severe uveitis was found
in 1.3% of patients in the MARINA study, and episodes of mild to
severe acute intraocular inﬂammation were found in up to 10% of
patients with AMD treated with monthly 0.5 mg ranibizumab
intravitreal injections in the 2-year ANCHOR study.3
In a retrospective cohort study of 193 eyes receiving a total of
693 bevacizumab intravitreal injections, nine patients were found
to have serious acute intraocular inﬂammation, of whom one pa-
tient developed inﬂammation-induced glaucoma which required
surgical intervention.24 Sniegowsky et al25 also reported a patient
with a sustained increase in IOP after intravitreal injections of
bevacizumab and ranibizumab which was associated with trabe-
culitis. As most patients do not routinely receive a complete slit-
lamp examination on the 1st day after an intraocular injection in
clinical practice or even in clinical trials,1,2 it is possible that the
incidence of transient intraocular inﬂammation may be more
prevalent than previously reported. Repeated transient intraocular
inﬂammation may progressively damage the trabecular meshwork
and subsequently cause sustained OHT in patients receiving mul-
tiple intravitreal anti-VEGF injections. A third possible mechanism
is an obstructing effect of small particles on the trabecular mesh-
work. Several workers have found that small silicone oil micro-
droplets or protein aggregates may develop in bevacizumab
repackaged by local pharmaceutical companies.26e29 Other mech-
anisms may include trabecular damage as a result of repeated IOP
spikes or repeated trauma by intravitreal injection procedures.
There are several possible explanations for the lack of delayed
OHT or increased mean IOP in our patients with AMD treated
with intravitreal anti-VEGF injections. One possibility is the use
of short-term postoperative topical corticosteroids for the pre-
vention of injection-associated transient intraocular inﬂamma-
tion. We routinely prescribed topical 0.1% prednisone acetate
four times a day for patients to use for 3 days after the pro-
cedures. This may have helped to prevent repeated transient
inﬂammation after injection and the subsequent development of
sustained increased IOP.
Another possibility is that delayed OHT may be induced by the
accumulative effect of mechanisms causing trabecular meshwork
obstruction, or damage caused after a large number of injections.
This theory is supported by recent studies conducted by Hoanget al18,19 in which treatment with a larger number of injections was
associated with a signiﬁcantly increased odds ratio of sustained
increased IOP, especially in the patients who received more than 29
injections for exudative AMD. Tseng et al16 also noted that large
increases in IOP were more often seen after many cumulative in-
jections (>20). In the current study, the maximum number of
intravitreal injections was 23, which may not be enough to develop
an increased mean IOP or delayed OHT. However, Good et al14 did
not ﬁnd an association between the occurrence of delayed OHT and
the number of injections. Other studies have reported persistent
OHT after one to two injections12 or after an average of four to ﬁve
injections.11,14 In the study conducted by Mencke et al,20 although
there was a trend of an increase in IOP with a longer follow-up
period, there was no signiﬁcant correlation between the number
of injections and an increase in IOP.
Another possible explanation for the lack of increased IOP or
sustained OHT in our study is that we did not use repackaged
bevacizumab which may have been altered by the micro-
aggregation of small particles such as silicone droplets or proteins.
All of our bevacizumab injections were freshly drawn from a new
vial that had not been repackaged or stored for more than 4 hours.
This may have effectively prevented the accumulation of small
particles which may accumulate and obstruct the trabecular
meshwork.
The possibility of cumulative IOP spikes may also have been
prevented by our method of pre-injection anterior chamber aspi-
ration with an aqueous aliquot. Although we used 0.1 mL of bev-
acizumab instead of the usual 0.05 mL used by most workers, the
pre-injection anterior chamber tapping may have essentially
counterbalanced possible IOP spikes immediately after the intra-
vitreal injections of bevacizumab.
The percentage of pre-existing glaucoma in our study (18.2%)
was much higher than the prevalence of glaucoma in the general
Asian population of people older than 50 years, which has been
reported to be around 3.2% to 3.7%.30,31 According to a pilot study in
2006, the prevalence of glaucoma in people older than 60 years was
only 4.4% in Taiwan.32 Higher prevalence was also found in the
studies of Good et al14 (21/215 eyes; 9.8%) and Wehrli et al21 (32/
302 eyes, 10.6%). As there is no report of a higher prevalence of
glaucoma in exudative patients with AMD, further larger scale
studies are needed to elucidate this issue.
The limitations of this study include its retrospective nature, the
small number of injections, and the relatively small number of
patients. However, our follow-up protocol of patients with exuda-
tive AMD treated with anti-VEGF required strict monthly follow-up
visits with complete ocular examinations, including IOP measure-
ments, until a lack of recurrence of disease activity was noted for
more than 6 months. Only then was the follow-up schedule
extended to 2-month to 3-month intervals. We believe this strategy
may have minimized undiscovered cases of increased IOP, thus
making our ﬁndings closer to a real-life situation.
In conclusion, the ﬁndings of the current study of a population
of Taiwanese patients with exudative AMD showed that repeated
intravitreal anti-VEGF injections of bevacizumab or ranibizumab, or
both, did not increase the risk of increased IOP whether or not the
patients had glaucoma. As there is still lack of consistency as to
whether or not an increase in mean IOP or sustained OHT is a
consequence of repeated intravitreal injections, further larger scale
prospective studies are needed to clarify this conclusion.References
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